CDKN2A and acute myeloid leukemia: Also, mutations in the NPM1 gene, observed in 30% of the patients suffering from acute myeloid leukemia (AML), result in aberrant cytoplasmic protein localization that may contribute to leukemogenesis through disruption of the p14(ARF)- MDM2-p53 pathway and centrosomal duplication [26]–[28].